-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Initiates Coverage On Cullinan Therapeutics with Buy Rating, Announces Price Target of $33

Benzinga·02/17/2026 15:05:27
Listen to the news
Citigroup analyst Samantha Semenkow initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $33.